627.50
-2.79%
Motilal Oswal
Laurus Labs (LAURUS) delivered better-than-expected revenue in 4QFY24.
However, EBITDA/PAT missed our estimates due to lower sales in the CDMO
segment and weak pricing in the other API segment.
Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.
More from Laurus Labs Ltd.
All Rapid Results
Recommended